Skip to main content
Geoffrey Uy, MD, Oncology, Saint Louis, MO

GeoffreyLimUyMD

Oncology Saint Louis, MO

Hematologic Oncology

Professor of Medicine, Washington University School of Medicine

Dr. Uy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Uy's full profile

Already have an account?

  • Office

    4921 Parkview Pl
    # Dv
    Saint Louis, MO 63110
    Phone+1 314-454-8304
    Fax+1 314-454-5902

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2003 - 2007
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2001 - 2003
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2001

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2020 - 2026
  • MO State Medical License
    MO State Medical License 2002 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
    Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
  • Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation  
    M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

  • CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death
    Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
    Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
    Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • You Make the Call: How Would You Treat This Transplant-Ineligible Patient with Ph+ ALL?
    You Make the Call: How Would You Treat This Transplant-Ineligible Patient with Ph+ ALL?September 30th, 2021
  • MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
    MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual MeetingDecember 11th, 2019
  • GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML
    GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AMLApril 23rd, 2019
  • Join now to see all

Grant Support

  • Targeting Leukemia Stromal Interactions In AMLNational Cancer Institute2009–2011

Professional Memberships